Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 26, Issue 4, 2008, Pages 650-656

  Socinski, Mark A ^a   Novello, Silvia ^b   Brahmer, Julie R ^b   Rosell, Rafael ^b   Sanchez, Jose M ^b   Belani, Chandra P ^b   Govindan, Ramaswamy ^b   Atkins, James N ^b   Gillenwater, Heidi H ^b   Pallares, Cinta ^b   Tye, Lesley ^b   Selaru, Paulina ^b   Chao, Richard C ^b   Scagliotti, Giorgio V ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; PEMETREXED; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; SUNITINIB; VASCULOTROPIN; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DEPRESSION; DIARRHEA; DISEASE DURATION; DISEASE FREE SURVIVAL; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PATHOGENESIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; XEROSTOMIA; CANCER STAGING; CAUSE OF DEATH; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; LUNG TUMOR; MIDDLE AGED; MORTALITY; NAUSEA; PATHOLOGY; REMISSION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CAUSE OF DEATH; CISPLATIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PAIN; PROTEIN-TYROSINE KINASES; PYRROLES; REMISSION INDUCTION; STOMATITIS; TREATMENT OUTCOME;

EID: 39149120621     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.9303     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
2. Yuan A, Yu CJ, Kuo SH, et al: Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19:432-441, 2001
3. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, et al: Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 75:477-481, 1997
4. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al: Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82:1427-1432, 2000
5. Shikada Y, Yonemitsu Y, Koga T, et al: Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 65:7241-7248, 2005
6. Shepherd FA: Angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 34:S81-89, 2001 (suppl 3)
7. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
8. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
9. Fehrenbacher L, O'Neil VJ, Belani CP, et al: A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Slide presentation at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, Atlanta, GA. Available at http://www.asco.org
10. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
11. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
12. O'Farrell AM, Abrams TJ, Yuen HA, et al: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605, 2003
13. Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766, 2003
14. Toner GC, Mitchell PL, De Boer R, et al: PET imaging study of SU11248 in patients with advanced malignancies. Proc Am Soc Clin Oncol 22:191, 2003 (abstr 767)
15. Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006
16. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006
17. Casali PG, Garrett CR, Blackstein ME, et al: Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. Proc Am Soc Clin Oncol 24:523s, 2006 (abstr 9513)
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
19. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:29-41, 1958
21. Brookmeyer R, Crowley JJ: A confidence interval for the median survival time. Biometrics 38: 29-41, 1982
22. Potapova O, Laird AD, Nannini MA, et al: Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase receptor inhibitor SU11248. Mol Cancer Ther 5:1280-1289, 2006
23. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
24. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
25. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
26. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000
27. Brahmer J, Govindan R, Novello S, et al: Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study. J Clin Oncol 25:7542, 2007 (suppl)
28. Socinski MA, Novello S, Sanchez JM, et al: Efficacy and safety of sunitinib in a multicenter phase II trial of previously treated, advanced non-small cell lung cancer (NSCLC). Ann Oncol 17:729PD, 2006 (suppl 9)
29. Gatzemeier U, Blumenschein G, Fosella F, et al: Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. Proc Am Soc Clin Oncol 24:18S, 2006 (abstr 7002)